Home » Posts tagged 'dr balaji ganeshan'
Tag Archives: dr balaji ganeshan
Feedback #FDBK – Presentation at RSNA 2017
Feedback plc (AIM: FDBK), the specialist medical imaging technology company, announces that Dr Balaji Ganeshan will be presenting at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA 2017”) taking place from 26 November to 1 December 2017 in Chicagbalajio (IL), USA.
The details for the oral presentation on the study undertaken at the Institute of Nuclear Medicine, University College London, UK are as follows:
Date and session time: Wednesday 29 November at 15:00 – 16:00 CST
Title: Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults with Neuro-Endocrine Cancers Treated with 177Lu-DOTATATE
Abstract number: SSM13-06
Session: Molecular Imaging (Analysis and Quantification)
Room: S504C
Presenter: Balaji Ganeshan, PhD
Two additional papers co-authored by Dr Balaji Ganeshan will be presented at RSNA 2017; one by Seoul National University and University College London focused on liver cancer (abstract SSK07-05), and one by Cambridge University, the University of Rome and University College London focused on ischemic stroke (abstract SSQ15-02). Overall, RSNA 2017 is expected to include at least 18 scientific paper presentations featuring TexRAD® Computed Tomography Texture Analysis (CTTA) and Magnetic Resonance Texture Analysis (MRTA), many of which have won awards in this year’s RSNA categories. Further information can be found at https://rsna2017.rsna.org/program.
Dr Balaji Ganeshan, Director of New Business at Feedback plc, said: “RSNA is the premier global event for radiologists and the increasing focus on our TexRAD® technology is encouraging. As seen in previous years, our renowned customers will highlight multiple TexRAD® presentations across various disease indications, further emphasising the significance of our technology across the healthcare industry. We look forward to discussing TexRAD® with this year’s RSNA delegates.”
TexRAD® is the Company’s patented quantitative image texture analysis technology for diagnostic radiological scans. The technology has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer, or other disease indications, and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. By analysing the texture features in computerised tomography (CT) scans, magnetic resonance images (MRI) and positron emission tomography scans (PET/CT), TexRAD®‘s quantitative imaging capabilities provide clinicians with additional, visually imperceptible information to make better decisions in order to improve patient outcomes.
TexRAD® research to date has shown great potential in many different oncological and non-oncological sites. In particular, the papers being presented at RSNA 2017 focus on liver, pancreatic, kidney, cervical, oral, genitourinary, head & neck, thyroid, neuroendocrine and endometrial cancers, as well as gastrointestinal stromal tumours, gliomas, thymic-epithelial neoplasms and carotid-plaques. On 20 November 2017, Feedback announced the CE marked release of TexRAD® Lung, a “software only” Class 1 medical device, to help advance lung cancer diagnosis. Further information on the TexRAD®technology can be found at www.texrad.com.
– Ends –
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadranplatform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.
For further information, please contact:
|
Feedback plc Dr Alastair Riddell, Chairman Lara Mott, Investor Relations
|
Tel: 01954 718072 hello@fbk.com |
Feedback (FDBK) – TexRAD sponsor Mumbai American British Course in Neuroradiology
Dr Balaji Ganeshan from TexRAD Ltd, sponsors of the Octobers 6th American British Course in Neuroradiology @ABCNR 2017 at Mumbai. Pictured are Dr Ganeshan, Dr Tufail Patankar, Consultant Interventional Neuroradiologist, Leeds Teaching Hospitals NHS Trust, UK and Dr Kshitij Mankad, Consultant Pediatric Neuroradiologist, Great Ormond Street Hospital,Hon. Sr Clinical Lecturer, UCL, London.
Dr Balaji Ganeshan presents TexRAD at the prestigious Beijing Society of Radiology Conference – Feedback Plc (FDBK).
Dr Balaji Ganeshan presents TexRAD at the prestigious Beijing Society of Radiology Conference.
On Saturday September 9th 2017, Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc gave a keynote lecture entitled “TexRAD Texture Analysis of CT and MR images – ready for prime time?” at the prestigious Beijing Radiation Academic Annual Conference.
Dr. Ganeshan spoke on CT and MRI texture analysis in cancer imaging which is a very topical area of interest in medical imaging and TexRAD is at the forefront of this development. Evidence that currently supports the potential use of TexRAD in different clinical applications and its utility as part of the qualification process for its use in routine clinical practice was further discussed.
Pictures below show Dr Ganeshan receiving a Certificate of Appreciation from Professor H.D.Xue – Assistant Director of Radiology at Peking Union Medical College Hospital and a Committee member of the Beijing Society of Radiology.
Pictures below show Dr Ganeshan with Xiaowei Ni, CEO of Boya Digital Technology (Beijing) Co. Ltd, and members of the GE-China team including Zhuang Wei, Director of HCIT-GE-China. Dr Ganeshan is also shown with members of the GE-China team outside Beijing University Third Hospital.
Cancer Care Commission (CCC) is a UK company based in Oxford working with NHS trusts to help improve their clinical pathways for cancer care. CCC are partnering with China Resources Phoenix Health Group (CRPHG), who are a very large company owning over a hundred health facilities. CRPHG own Beijing-Yanhua-Hospital, and are partnering with Beijing 5th cancer hospital and CCC to try and create a centre of excellence for cancer care in North China. Pictures below show Dr Ganeshan presenting TexRAD with Boya CEO Xiaowei Ni, Dr Fred Sun, Sudhakar Jayaram, Dr Hongxia Yu and Dr Dadong Li, UK Trade & Investment Manager, Life Science. Dr Li’s team organised the meeting at Yanhua hospital.
Feedback (FDBK) subsidiary CCI signs exclusive agreement with Boya Digital Technology (Beijing) to distribute TexRAD in China
Feedback plc is pleased to announce that its subsidiary, Cambridge Computed Imaging Ltd, has signed an exclusive distributor agreement with Boya Digital Technology (Beijing) Co. Ltd., based in Beijing, China, for sales and distribution of its TexRAD® texture analysis research software in the People’s Republic of China. Boya is an approved vendor to GE Healthcare China, Beijing and is facilitating the purchase and installation process of TexRAD research software on behalf of GE in the PRC.
TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI). As in western countries, university hospitals and research institutions in China are increasingly using innovative software such as TexRAD to generate new knowledge and insights in the fight against cancer and other diseases. The Agreement ensures user access and customer support for TexRAD within the rapidly growing market for medical research in the PRC.
Feedback regards the completion of this Agreement as a significant step in the continuing development of its global sales and market presence as outlined in recent investor presentations.
Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc said; “We are delighted to have formalised the business relationship with both Boya and GE. This follows discussions at the Beijing Society of Radiology in 2016 and involvement in the installation of TexRAD software in a leading medical institution, Peking Union Medical College Hospital, Beijing. I look forward to working with Boya and GE to develop awareness of the capabilities of TexRAD and sales to the medical research community in China.”
Ian McLellan, Commercial Director CCI Ltd commented; “The signing of this Agreement with Boya represents an excellent basis on which to develop our sales and presence in this exciting growth market using the expertise and customer reach of Boya Digital Technologies. We look forward to developing the TexRAD revenue potential and increasing the market reach to our users.”
Ni Xiaowei, President Boya Digital Technologies confirmed; “We are pleased with the addition of TexRAD to our software portfolio, and look forward to working with CCI to promote this texture analysis software to research institutes in leading hospitals within the People’s Republic of China. I anticipate a very successful business relationship, working closely with Dr Balaji Ganeshan and CCI. Boya Digital Technologies has developed a strong reputation for IT sales and support with our customers which we can offer to support the development of TexRAD sales in China.”
|
Feedback plc
|
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker)
|
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker)
|
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
|
Brand Communications |
Tel: 07976 431608 |
About CCI
CCI Ltd is owned by AIM listed Feedback Plc (FDBK), based in Bourn, Cambridge UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.
About Boya
Boya Digital Technologies, founded in 2004 is based in Beijing, China and has been a manufacturer and supplier of computers, peripherals and software for over 10 years. It is a re-seller and vendor to a number of companies in China. Boya is part of the larger corporate organization, Boya Software Co Ltd, which aims to create value for its customers through technology and services.
About TexRAD
TexRAD is a highly advanced, patented image texture analysis software tool that analyses the textures in routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications. TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc.
Feedback (FDBK) subsidiary Cambridge Computed Imaging announces exclusive distributor arrangement with Korea Computer Motion ISG
Feedback plc subsidiary Cambridge Computed Imaging Ltd (CCI) is pleased to announce the signing of an Exclusive Distributor arrangement with Korea Computer Motion ISG (Korea ISG) based in Seoul, South Korea for sales and distribution of its TexRAD® texture analysis research software.
TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI) in South Korea.
As outlined in our recent investor presentations, this is a significant step for CCI Ltd as part of its plans to expand sales of TexRAD software to meet the fast-growing demand in Asian markets, identifying and engaging with distributors who are experts in the local market, and who can leverage the TexRAD brand awareness to help build a regional sales pipeline.
Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc said; “We are pleased to sign this significant Distributorship agreement with Korea ISG to support the interest and acceptance of TexRAD in the rapidly growing and important South Korean medical imaging research market. We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase the TexRAD revenue potential and market reach and meet our customer needs.”
Mr Jacob Woo, CEO of Korea ISG commented; “We are pleased to have started to work with CCI Ltd this year to promote the highly acclaimed TexRAD texture analysis software in South Korea which has attracted a lot of interest amongst the top University Hospitals who are also our potential-customers. Following a recent installation for research at the prestigious Korea University Hospital, I anticipate a very successful business relationship, rapidly increasing TexRAD software sales and working closely with Dr. Balaji Ganeshan and CCI. Our team has a first class reputation amongst researchers in the region, and offers unrivalled in-depth market-access and know-how in South Korea.”
About CCI
CCI Ltd is owned by AIM listed Feedback Plc (FDBK), based in Bourn, Cambridge UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.
About Korea Motion ISG
Korea ISG has installed and supported MRI/CT 3D processing imaging software to about 120 prominent Korean hospitals for 23 years, and is the largest medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.
About TexRAD
TexRAD is a highly advanced, patented image texture analysis software tool that analyses routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications.
Contact for press enquiries
CCI Ltd: Mike Hayball, CEO Tel: 01954 718055
TexRAD Ltd: Dr. Balaji Ganeshan, CEO Tel: 01954 718072
Feedback plc: Alastair Riddell, Chairman Tel: 01954 718072
Brand Communications: Alan Green Tel: 07976 431608
Proactive Investment Overview – Feedback PLC’s eye on the prize: a CE mark for TexRAD
The CE mark will enable Feedback to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales.
Dr Alastair Riddell’s CV reveals a high-flying career with the forerunners of what are now GE Healthcare, Johnson & Johnson and Pfizer, followed by spells guiding businesses to IPO or trade sale.
So, what attracted him to the challenge of Feedback plc (LON:FDBK), an AIM-listed medical imaging firm worth less than £9mln?
“The persistence of Tom Charlton, who would not give me any peace until I said yes,” jokes Riddell.
Charlton is one of Feedback’s major shareholders who recruited the Riddell as chairman.
However, Riddell’s mind was actually made up by cold hard data that underscored the potential of its main product, TexRAD.
“When I went to Cambridge and spoke to the people who do the work there it became clear there was real potential in this,” he told Proactive Investors.
“What really convinced me was a small study they’d done.”
Before we get to that study, it is worth getting a feel for TexRAD does.
It was the brainchild of the PhD of Dr Balaji Ganeshan, an expert on textural analysis of images gleaned from computed tomography (CT) scans.
Distilled down to the basics, it is essentially a very smart piece of software that analyses medical images, to reveal features that are not always evident to the human eye.
In doing so, it may “in a very statistical, objective and numerical way relate the output to a prognosis for the patient”, says Riddell.
Ganeshan carried out a study of patients with liver cancer using TexRAD and the results were, in the words of the Feedback chairman, “quite remarkable”.
“It quickly dawned on me that this could be a really valuable objective tool for giving an accurate prognosis,” he adds.
Riddell was announced as chairman in June 2016, and the focus has been on getting Feedback on to a commercial footing.
In April 2017 the company raised £750,000, issuing shares at 2.75p a pop, to invest in product development plus sales & marketing – mostly for TexRAD.
The fund-raising came in the wake of a breakthrough deal at the end of March that should see its TexRAD Lung product available on the diagnostic imaging platform of a leading global imaging company.
Feedback is already making money from TexRAD with sales to institutions carrying out research, but the promised land is filled with deals such as the TexRAD Lung partnership.
To fully commercialise the TexRAD product it must be granted a CE Mark, European certification for the technology.
It was on track to get this by the end of May 2017 but then it identified several new enhancements that will improve performance.
While that is good news, the discoveries mean that the award of the CE mark will be delayed “by several weeks”.
When it gets the thumbs-up from the EU, the mark will enable it to sell TexRAD to hospitals, where it will lend numerical support to the very skilled, interpretative work carried out by radiologists.
Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.
Sales of the current product, though modest, reveal there is demand from a very specialist audience in the research sphere.
It means the technology is being cited in literature by some of the leading centres for cancer research – providing a great endorsement of the TexRAD from key opinion leaders.
In fact, the technology is also starting to make an impression with businesses operating in the field.
“My view is at the moment we are far too small and far too young to be engaged in corporate discussion,” says Riddell.
“But, if we can grow sales the way I hope we can grow them, then in two or three years we might look differently at these corporate approaches.”
In the meantime, it is about “investing in the company and doing things to a particular standard”, the Feedback chairman says.
“Of course, the next milestone will be getting the CE Mark for TexRAD,” he adds.
“This will enable us to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales.”
Read the full article on the Proactive Investors website here
Feedback (FDBK) – Issue of Equity
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce the completion of a placing of 27,272,727 new ordinary shares of 0.25p each in the Company at a price of 2.75 pence per Placing Share to raise a total of £750,000 (before expenses). The Placing is subject to admission of the Placing Shares to trading on AIM. Application has been made for the Placing Shares to be admitted to trading on AIM and it is expected that Admission will take place on 2 May 2017.
The net proceeds from the Placing will be used to invest in product development, sales and marketing, primarily for TexRAD, Feedback’s patented quantitative medical imaging software, as well as for general working capital purposes.
The Placing Shares will represent, in aggregate, approximately 11.08 per cent. of the Company’s issued ordinary share capital as enlarged by the issue of the Placing Shares. The Placing was conducted within the Company’s existing share allotment authorities. The Placing Shares, when duly issued and fully paid, will rank pari passu in all respects with the Company’s existing ordinary shares. The Placing has not been underwritten.
On Admission, the shareholdings of those directors who hold shares in Feedback will be as follows:
|
Director |
Holding of ordinary shares |
Percentage of Enlarged Share Capital |
|
Dr Alastair Riddell (Non-executive Chairman) |
5,000,000 |
2.03% |
|
Dr Balaji Ganeshan (Executive Director) |
2,860,000 |
1.16% |
|
Mike Hayball (Executive Director) |
5,670,600 |
2.30% |
|
Tom Charlton (Non-executive Deputy Chairman) |
59,637,408 |
24.27% |
|
Trevor Brown (Non-executive Director) |
55,089,111 |
22.39% |
Total Voting Rights
The Placing is conditional, among other things, upon Admission becoming effective. Following Admission, the Company’s issued ordinary share capital will consist of 246,066,584 ordinary shares, with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company will be 246,066,584. With effect from Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
**ENDS**
For further information, please contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
|
Brand Communications |
Tel: 07976 431608 |
Feedback Chairman Dr Alastair Riddell discusses TexRAD Lung and other developments with Proactive’s Andrew Scott
Dr Alastair Riddell, chairman of Feedback (LON:FDBK) tells Proactive Investor’s Andrew Scott their TexRAD Lung product could soon be available on the diagnostic imaging platform of a leading global imaging company.
Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD
Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD – Preliminary Findings
Presentation at Society of Abdominal Radiology (SAR) Annual Conference
Sahand Sohrabi and Raghunandan Vikram – Diagnostic Imaging, MD Anderson Cancer Center, Houston, Texas, USA
Purpose: To investigate role of CT Texture analysis (CTTA) and mutational status of clear cell renal cell carcinoma (ccRCC).
Materials and Methods: Multi-phase contrast enhanced CT (CECT) including Non contrast (NC), Corticomedullary (CM), nephrographic (N) and excretory (E) of 107 patients with ccRCC from the Cancer Imaging achive underwent filtration-histigram based CTTA using a commercially available research software (TexRAD Ltd). Using the DICOM images, filtration step extracted texture features using different spatial scale filters corresponding to fine, medium and coarse texture scales followed by histogram quantification: Mean gray-level pixel intensity, Entropy, Standard Deviation (SD), Mean of positive pixels (MPP), Kurtosis and Skewness. Non-parametric Mann Whitney test was used to test for significant associations in CTTA with mutational status (VHL, BAP1, PBRM1, SETD2, P13K pathway regulators.
Results: NC study showed statistically significant differences in the CT derived textual features between the mutational status of BAP1 (entropy p=0.045; SD p=0.033; MPP p=0.03), VHL (mean p=0.049, SD0.031), P13 pathway regulator (mean p=0.021, SD p=0.03, MPP p=0.03, skewness p=0.048) and PBRM1 (skewness p=0.048). Differences in CTAA measurements were seen in all phases in patients with VHL mutational status. These were most marked in the CM phase (mean p=0.031, SD p=0.006, entropy p=0.03, MPP p=0.005 and Kurtosis p=0.049). CTA measurements in Excretory phase images were useful in differentiating between BAP one mutations (entropy p=0.045, skewness p=0.035) and PBRM1 mutations (entropy p=0.023).
Conclusions: A software-based CT Texture Analysis can derive features that may help identify patients with genetic mutations in patients with ccRCC.
Dr Balaji Ganeshan, Director of New Business at Feedback Plc stated, “In our trading update of March 30th 2017, we stated that purchase orders for the well-established research version of TexRAD continued at a good rate ahead of the impending release of the first clinical version. This study is the latest in a number of published papers that serves to demonstrate the value and diversity of TexRAD for CTTA applications, and further underscores the progress highlighted in the trading update. We remain focussed on obtaining the CE mark for TexRAD Lung by the target date of May 2017.”
Abdominal Radiology – Study using texture analysis (TexRAD) of the liver at MDCT for assessing hepatic fibrosis – Feedback plc
By Lubner MG, et al. Abdom Radiol (NY). 2017. Source PubMed.
PURPOSE: To evaluate CT texture analysis (CTTA) for staging of hepatic fibrosis (stages F0-F4) METHODS: Quantitative texture analysis (QTA) of the liver was performed on abdominal MDCT scans using commercially available software (TexRAD), which uses a filtration-histogram statistic-based technique. Single-slice ROI measurements of the total liver, Couinaud segments IV-VIII, and segments I-III were obtained. CTTA parameters were correlated against fibrosis stage (F0-F4), with biopsy performed within one year for all cases with intermediate fibrosis (F1-F3).
RESULTS: The study cohort consisted of 289 adults (158M/131W; mean age, 51 years), including healthy controls (F0, n = 77), and patients with increasing stages of fibrosis (F1, n = 42; F2 n = 37; F3 n = 53; F4 n = 80). Mean gray-level intensity increased with fibrosis stage, demonstrating an ROC AUC of 0.78 at medium filtration for F0 vs F1-4, with sensitivity and specificity of 74% and 74% at cutoff 0.18. For significant fibrosis (≥F2), mean showed AUCs ranging from 0.71-0.73 across medium- and coarse- filtered textures with sensitivity and specificity of 71% and 68% at cutoff of 0.3, with similar performance also observed for advanced fibrosis (≥F3). Entropy showed a similar trend. Conversely, kurtosis and skewness decreased with increasing fibrosis, particularly in cirrhotic patients. For cirrhosis (≥F4), kurtosis and skewness showed AUCs of 0.86 and 0.87, respectively, at coarse-filtered scale, with skewness showing a sensitivity and specificity of 84% and 75% at cutoff of 1.3.
CONCLUSION: CTTA may be helpful in detecting the presence of hepatic fibrosis and discriminating between stages of fibrosis, particularly at advanced levels.
Dr Ganeshan, Director of New Business at Feedback Plc stated, “This study, and a number of others recently published in the run up to the European Congress of Radiology at the start of March serves to demonstrate the broad range of existing and potential new applications for TexRAD software. The recent high profile press coverage of MRI scan analysis for prostate cancer highlighted TexRAD’s potential to enhance early discovery of significant cancers. Similarly this study of texture analysis of the liver on routinely acquired CT scans highlights the potential of TexRAD to act as a non-invasive biomarker (tool) in the diagnosis of hepatic fibrosis and assessment of severity of the disease. This can potentially assist in minimising the need for frequent liver biopsies and additional examinations.”
Link here to view the PubMed article